RAF isoform selectivity of MEK inhibitors and rational design of a covalent ARAF-MEK inhibitor
Year: 2025
Type: article
Language: en
Topic: Melanoma and MAPK Pathways
Authors and affiliations:
raw_author_name: Sayan Chakraborty
raw_affiliation_strings: Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
raw_author_name: Jie Jiang
raw_affiliation_strings: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
Department of Medicine, Harvard Medical School, Boston, MA02215, USA
raw_author_name: Javier Vinals Camallonga
raw_affiliation_strings: Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
raw_author_name: Dimitris Gazgalis
raw_affiliation_strings: Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
raw_author_name: Thomas W. Gero
raw_affiliation_strings: Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
raw_author_name: Maurício T. Tavares
raw_affiliation_strings: Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
raw_author_name: Georgia Dittemore
raw_affiliation_strings: Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
raw_author_name: Emre Tkacik
raw_affiliation_strings: Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
raw_author_name: Dong Man Jang
raw_affiliation_strings: Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
raw_author_name: Byung Hak Ha
raw_affiliation_strings: Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
raw_author_name: Felix H. Gottlieb
raw_affiliation_strings: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
Department of Medicine, Harvard Medical School, Boston, MA02215, USA
raw_author_name: Talya Levitz
raw_affiliation_strings: Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
raw_author_name: Rebecca J. Metivier
raw_affiliation_strings: Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
raw_author_name: Anna M. Schmoker
raw_affiliation_strings: Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
raw_author_name: David A. Scott
raw_affiliation_strings: Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
raw_author_name: Hyesung Jeon
raw_affiliation_strings: Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
raw_author_name: Pasi A. Jänne
raw_affiliation_strings: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
Department of Medicine, Harvard Medical School, Boston, MA02215, USA
raw_author_name: Michael J. Eck
raw_affiliation_strings: Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA